Reinhart Partners LLC. Has $11.62 Million Stake in Avantor, Inc. (NYSE:AVTR)

Reinhart Partners LLC. increased its stake in Avantor, Inc. (NYSE:AVTR) by 3.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 551,273 shares of the company’s stock after purchasing an additional 20,540 shares during the quarter. Reinhart Partners LLC.’s holdings in Avantor were worth $11,615,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board lifted its holdings in Avantor by 6.8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock worth $486,059,000 after purchasing an additional 1,463,695 shares during the last quarter. State Street Corp lifted its holdings in Avantor by 58.0% in the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after purchasing an additional 8,206,695 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Avantor by 18.2% in the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock worth $457,710,000 after purchasing an additional 2,719,615 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Avantor by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 11,150,788 shares of the company’s stock worth $287,791,000 after purchasing an additional 739,667 shares during the last quarter. Finally, 1832 Asset Management L.P. lifted its holdings in Avantor by 1,634.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after purchasing an additional 8,038,451 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on AVTR. Wells Fargo & Company cut their price target on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Robert W. Baird cut their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. Barclays cut their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, UBS Group cut their price target on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Avantor presently has an average rating of “Moderate Buy” and a consensus target price of $27.69.

Avantor Price Performance

Avantor stock traded up $0.24 during mid-day trading on Monday, hitting $21.90. 2,919,948 shares of the company were exchanged, compared to its average volume of 3,133,666. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The business has a fifty day moving average of $21.52 and a 200 day moving average of $23.35. Avantor, Inc. has a 1-year low of $19.59 and a 1-year high of $28.00. The company has a market capitalization of $14.91 billion, a PE ratio of 47.61, a price-to-earnings-growth ratio of 2.75 and a beta of 1.28.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.